TAO Synergies Inc. (TAOX) stock
Close on Nov 12, 2026Market cap $16.84MP/E –Yield –
TAO Synergies Inc. reported revenue of $772.50K for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $16.84M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $16.84M
- P/E ratio
- –
- Price to sales
- 21.80
- Price to book
- 1.32
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $772.50K
- Net income
- -$16.65M
- EPS, diluted
- -$8.81
- Book value per share
- $1.71
- Diluted shares
- 7M
Trading
- Previous close
- $2.54
- Open
- $2.46
- Day's range
- $2.23 – $2.50
- Volume
- 83,249
- Average volume (20 days)
- 113,583
- Beta (5 years)
- 1.73
- 52-week range
- $2.17 – $8.03
- RSI (14 days)
- 30.4
- Volatility (1 year)
- 97.3%
- Relative volume
- 0.57×
- WACC
- 13.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TAOX | S&P 500 | Difference | TAOX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -40.2% | -2.7% | −37.5 pts | ||
| 3 months | -35.3% | -1.7% | −33.6 pts | ||
| Year to date | -38.9% | +11.9% | −50.8 pts | ||
| 1 year | -70.3% | +12.0% | −82.2 pts | ||
| 3 years | -65.2% | +78.2% | −143.4 pts | -29.7% | +21.2% |
| 5 years | -99.3% | +73.2% | −172.5 pts | -62.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases TAO Synergies filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About TAO Synergies
Finance Services
TAO Synergies Inc., formerly known as Synaptogenix, Inc., is a clinical-stage biopharmaceutical company that also operates a cryptocurrency treasury and media initiative. The company primarily develops its lead drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease and other neurodegenerative conditions such as Fragile X syndrome. Additionally, it operates a long-only cryptocurrency treasury strategy focused on accumulating and staking TAO tokens on the Bittensor decentralized artificial intelligence network to generate revenue. The company also produces news, insights, and podcasts covering the Bittensor ecosystem through its TAO Daily platform. Because its biopharmaceutical candidates remain in development, its target beneficiaries include patients with cognitive disorders, alongside participants and investors in the decentralized machine learning sector.
Company profile, executives and historyTAO Synergies stock: common questions
What is TAO Synergies's stock price?
TAOX closed at $2.25 on Nov 12, 2026, down 11.42% on the day. Over the past 52 weeks it traded between $2.17 and $8.03.
What is TAO Synergies's market cap?
TAO Synergies was worth $16.84M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TAOX's P/E ratio?
TAO Synergies lost money over fiscal 2025 (diluted EPS -$8.81), so it has no meaningful P/E ratio.
How much revenue does TAO Synergies make?
TAO Synergies reported revenue of $772.50K for the twelve months to Jun 30, 2026.
Does TAO Synergies pay a dividend?
No. TAO Synergies has not paid a cash dividend over the last twelve months.
How has TAOX stock performed over the past year?
Including dividends, TAOX returned -70.3% over the past year, against +12.0% for the S&P 500.
How many TAOX shares are sold short?
0M shares were sold short at the latest FINRA report, 5.69% of the float, or 3.7 days of average trading volume.
Who are TAO Synergies's competitors?
Companies most similar to TAO Synergies by business, industry and size include HYPD, BNBX, MWAI, SUIG, FGC.
See a number that looks wrong?